Skip to main content

A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

In this single-arm Phase 2 study, the researchers are assessing the feasibility of the group retreat format for clinicians and explores different 'doses' of preparation. A sequential dose-escalation design is used. The study will recruit healthcare clinicians (physicians, nurses, nurse practitioners, physician assistants) aged 25-70 years currently in clinical practice with moderate or greater symptoms of depression and loss of meaning during the past 5 years. Each participant will be in a group cohort of 8, and 3 cohorts will be tested at each dose level. The objectives are safety, feasibility, mechanism testing, and outcomes.

Status
planned
Phase
Phase 2
Institution
University of Washington
Principal investigator
Anthony Back, MD
Start date
2026-06-01
End date
2028-07-01
Registry ID
NCT07565909

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.